SignalChem Lifesciences Corporation (“SLC”), headquartered in British Columbia, Canada, is a clinical-stage company developing novel targeted therapies for oncology. Our unique business model has been built upon two important pillars: the Bioreagents and Research Services business and the Drug Discovery and Development business. A group of scientists with extraordinary expertise and experience in kinase biology and drug discovery are working together cohesively to provide the best products and services to our customers around the world and to maximize the efficiency of our own drug discovery efforts.
Parallel to our drug discovery efforts, SignalChem is taking advantage of our decades of biomarker research and assay development experiences with the aim to develop companion diagnostics to go along with our drug discovery programs. Our goal is to become a fully-integrated biopharmaceutical company capable of delivering transformative kinase inhibitor medicine to patients.